The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Whenever a new year begins, most of us strive to make some resolutions such as going to the gym, drinking less (aka, Sober ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

There are plenty of tips on how to lose weight fast without exercise, from sketchy pills to crash diets that do more harm ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...